Traditionally, cardiovascular disease including coronary artery diseases are treated by open-heart surgery through thoracotomy, which involves large chest incision and cardiopulmonary bypass. In the past two decades, interventional approaches to treat cardiovascular diseases become mature. Percutaneous coronary intervention has widely adopted to treat coronary artery disease, in substitution to coronary artery bypass grafting (CABG), an open-heart invasive procedure. In recent years, severe aortic stenosis patients who cannot tolerate traditional open-heart aortic valve replacement, have an alternative treatment options of transcatheter aortic valve implantation (TAVI). Compared with the traditional invasive approach, the emerging interventional TAVI procedure can be performed through a formal access site (14F-21F, 5mm-7mm), which provides less complications and shorter recovery time. The global interventional cardiology devices market is projected to reach an estimated US$25.2 billion by 2018 with a CAGR of 6.8%. The emerging interventional technologies, such as TAVI, are experiencing a double-digit growth in recent years.
Medeon Biodesign, Inc. is committed to develop cutting-edge minimally invasive medical solutions addressing urgent unmet medical needs in the cardiovascular field. The Company brings together clinical, regulatory, and quality expertise, as well as mechanical and material engineering professionals to provide solutions with safety and efficacy, ultimately to benefit physicians and patients.